Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Cumulative Effect, Period of Adoption, Adjustment	Common stock	Additional paid-in capital	Additional paid-in capital Cumulative Effect, Period of Adoption, Adjustment	Accumulated deficit	Accumulated deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated other comprehensive income
Beginning balance (in shares) at Dec. 31, 2020			11,661,797
Beginning balance at Dec. 31, 2020	$ 470,418		$ 116	$ 943,572		$ (472,138)		$ (1,132)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	9,849					9,849
Issuance of shares due to vesting of restricted shares (in shares)			71,146
Issuance of shares due to vesting of restricted shares			$ 1	(1)
Net unrealized gain on cash flow hedges	600							600
Fees for equity offerings	(32)			(32)
Cash used to settle net share equity awards	(811)			(811)
Stock-based compensation	872			872
Ending balance (in shares) at Mar. 31, 2021			11,732,943
Ending balance at Mar. 31, 2021	480,896		$ 117	943,600		(462,289)		(532)
Beginning balance (in shares) at Dec. 31, 2021			12,917,027
Beginning balance at Dec. 31, 2021	671,266	$ (12,050)	$ 129	982,746	$ (20,726)	(313,495)	$ 8,676	1,886
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	53,073					53,073
Dividends declared	(27,112)					(27,112)
Issuance of shares due to vesting of restricted shares (in shares)			60,890
Issuance of shares due to vesting of restricted shares			$ 1	(1)
Issuance of shares upon exercise of stock options (in shares)			8,077
Issuance of shares upon exercise of stock options	85		$ 0	85
Net unrealized gain on cash flow hedges	8,681							8,681
Fees for equity offerings	201			201
Cash used to settle net share equity awards	(1,862)			(1,862)
Stock-based compensation	1,487			1,487
Ending balance (in shares) at Mar. 31, 2022			12,985,994
Ending balance at Mar. 31, 2022	$ 693,769		$ 130	$ 961,930		$ (278,858)		$ 10,567